Monte Rosa Therapeutics, Inc. (GLUE) reported Q4 2025 GAAP loss of $0.55 per share, a wider loss than the -$0.34 estimate (63.4% wider). Collaboration revenue for Q4 2025 was $2.8 million
[EPS year-over-year comparison not available — do not compute from history] [Revenue year-over-year comparison not available — do not compute from history] Monte Rosa Therapeutics, Inc. recorded a net loss of $46.1M during the quarter.
Shares traded at $16.02. on volume of 616,447. The company has a market capitalization of $1.25B.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectivel…
A detailed analysis of Monte Rosa Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% first appeared on Alphastreet.
